UroGen Pharma Ltd. (URGN) Wednesday announced a licensing agreement with German pharmaceutical company Medac GmbH to develop a next-generation mitomycin-based formulation for urothelial cancers. The financial aspects of the association is not revealed. UGN-103 combines UroGen's RTGel technology with Medac's mitomycin.

UroGen Pharma Ltd.（URGN）周三宣布与德国制药公司Medac GmbH达成许可协议，开发用于尿路上皮癌的下一代丝裂霉素制剂。该协会的财务方面没有透露。UGN-103将UroGen的RTGel技术与Medac的丝裂霉素相结合。

UroGen said it plans to initiate a Phase 3 study in 2024 to explore the safety and efficacy of UGN-103 in LG-IR-NMIBC.Liz Barrett, CEO of UroGen said, 'The 80 mg formulation of mitomycin from Medac is specifically designed to be mixed with our RTGel technology, which may provide advantages for patients looking for non-surgical treatments for urothelial cancer.' For comments and feedback contact: editorial@rttnews.comBusiness News.

UroGen表示，计划于2024年启动一项3期研究，以探索UGN-103在LG-IR-NMIBC中的安全性和有效性。UroGen首席执行官利兹·巴雷特（LizBarrett）说，“Medac公司生产的80毫克丝裂霉素配方专门设计用于与我们的RTGel技术混合，这可能为寻求尿路上皮癌非手术治疗的患者提供优势。”如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股